The drug candidate is a humanized monoclonal IgG4 antibody and is administered through intravenous route. It is based on the (somatic hypermutation) SHM-XEL technology. GlobalData, the leading ...

The PubMed database was searched from January 2018 to May 2024. Articles were selected for inclusion if they reported on patients with metastatic prostate cancer who received a germline or somatic ...

Somatic workouts—a style of slow, mindful, body-focused exercise—have gained popularity as a remedy to society's collective elevated stress state. This type of training can help you dial ...

Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is ...

The pair had helped identify a still-unnamed disease, which they had tied to a particular gene and to a particular somatic mutation—a genetic change that had not been passed down from a parent ...

It is an anti-PD-1 mAb. The drug candidate acts by targeting the PD-1 which has the potential to activate anti-tumor immunity. The drug candidate is developed based on somatic hypermutation (SHM) ...

The BCR IGH is coded for by multiple genes, including VDJ genes. Only productive and functional IG rearrangements are retained in B-cells. IGH gene rearrangements in B-cells undergo additional somatic ...